Fundz

Who to call at Atavistik Bio, and when

Fundz watches for the moments Atavistik Bio starts buying, and tells you who to reach.

  • An alert the day Atavistik Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Atavistik Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Atavistik Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment.

Sep 25, 2026

Contract Type

partnership

CambridgeBiotechnologySoftwareHealth CareScience And Engineering

Description

Roche has made a significant investment by paying Atavistik Bio USD 70 million upfront as part of a research partnership. This partnership aims to advance innovative drug discovery efforts.

Quick answer

Roche enters a research partnership with Atavistik Bio with a USD 70 million upfront payment. (September 25, 2026). Atavistik Bio is based in Cambridge, Massachusetts, United States.

What agreement did Atavistik Bio announce on September 25, 2026?
Roche has made a significant investment by paying Atavistik Bio USD 70 million upfront as part of a research partnership. This partnership aims to advance innovative drug discovery efforts.
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology.
Where is Atavistik Bio based?
Atavistik Bio is based in Cambridge, Massachusetts, United States.

Source: Fundz verified event record.

Company Information

Company

Atavistik Bio

Location

Cambridge, Massachusetts, United States

About

Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.

Related People

Bryan
Likely contact at this company
••••••••@••••••••

See Bryan's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Atavistik Bio's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Atavistik Bio signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.